Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Cash Conversion Cycle : -9.56 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Parnell Pharmaceuticals Holdings's Days Sales Outstanding for the six months ended in Dec. 2018 was 18.55.
Parnell Pharmaceuticals Holdings's Days Inventory for the six months ended in Dec. 2018 was 90.59.
Parnell Pharmaceuticals Holdings's Days Payable for the six months ended in Dec. 2018 was 118.7.
Therefore, Parnell Pharmaceuticals Holdings's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2018 was -9.56.

Parnell Pharmaceuticals Holdings Cash Conversion Cycle Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Cash Conversion Cycle Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Cash Conversion Cycle

Get a 7-Day Free Trial

108.33

41.35

-9.21

-35.05

-9.56

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Cash Conversion Cycle	Get a 7-Day Free Trial			81.55	41.35	-9.21	-35.05	-9.56

Competitive Comparison of Parnell Pharmaceuticals Holdings's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Cash Conversion Cycle falls into.

Parnell Pharmaceuticals Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Parnell Pharmaceuticals Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2018 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	18.55	+	90.59	-	118.7
	=	-9.56

Parnell Pharmaceuticals Holdings's Cash Conversion Cycle for the quarter that ended in Dec. 2018 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	18.55	+	90.59	-	118.7
	=	-9.56

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Parnell Pharmaceuticals Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.